

Drug	ORR (%)	CRR (%)	PRR (%)	No. of patients	Phase	Setting	Reference
AZD1208	0	0	0	32	I	R/R	Cortes et al., Br J Cancer 2018
Cytarabine	32	32	0	81	III	R/R	Karanes et al., Leukemia Research 1999
Ganetespib	0	0	0	13	I/II	R/R	Lancet et al., Blood 2010
Imatinib*	3	0	3	36	II	R/R	Piccaluga et al., Haematologica 2007
Menin–MLL Inhibitor*	53	30	0	60	I/II	R/R	Issa et al., Nature 2023
Methotrexate	7.7	0	7.7	13	II	R/R	Kaspers et al., Pediatr. Blood Cancer 2006
Midostaurin	60			83	II	TN	Fischer et al., JCO 2010
MK-2206	5.6	5.6	0	19	II	R/R	Konopleva et al., Clin Cancer Res 2014
OTX015	13.9	8.3	5.5	36	I	R/R	Berthon et al., Lancet Haematol. 2016
Palbociclib	0	0	0	10	I	R/R	Kadia et al., Blood 2018
Panobinostat	5.1	5.1	0	59	II	R/R	Schlenk et al., Haematologica 2018
Quizartinib	69.4	48.2	21.2	245	III	R/R	Cortes et al., Lancet Oncol 2019
Rapamycin	44	0	4	9	I	R/R	Récher et al., Blood 2005
Ruxolitinib	7.7	7.7	0	13	I/II	R/R	Pemmaraju et al., Clin Lymphoma Myeloma Leuk 2015
Selinexor	14	8.6	3.7	81	I	R/R	Garzon et al., Blood 2017
Sunitinib	31	0	31	15	I	R/R	Fiedler et al., Blood 2005
Venetoclax	19	19	0	32	II	R/R	Konopleva et al., Cancer Discov 2016
Vismodegib	5.2	2.6	2.6	38	I	R/R	Bixby et al., Br J Haematol 2018
Volasertib	25	25	0	16	I	R/R	Bug et al., Blood 2011